Tag: ONCO

Blue Horseshoe Stocks: NSCT Exclusive CEO Interview

Cloud Medical Doctor Software Corp. NSCT

We’ll start things off this morning by turning our attention back to NSCT; we brought it into the fold for the first time this week as a longer-term play. The chart appeared to have to some ripening to do, as it searched for a bottom and yesterday’s session appears to have brought one. The came down to bounce off of the .0522-mark, and subsequently closed at its high-of-day .0648, a 24% intraday move.

In addition to seeing some early success on the NSCT chart this week, we had the honor of conducting an exclusive interview with the company’s CEO, Mr. Michael DeLaGarza via our sister site, Stock Traders Talk. It covers quite a bit, so we suggest you visit the site, or click the following graphic to bring up the interview straight away: 

HENDERSON, Nev., July 24, 2014 (GLOBE NEWSWIRE) — via PRWEB – The interview will be held on July 24, 2014 at 9:00 am EDT, An archived recorded version can be found on the homepage of Stock Traders Talk at http://www.stocktraderstalk.com, following the interview.

This interview will discuss Cloud-MD’s Software, services and our CipherShop Division which provides commercial quality, advanced, digital security solutions that comply with governmental regulatory requirements, such as HIPAA and SOX and their CipherLoc product suite offers both an advanced Polymorphic Cipher Engine and a Polymorphic Hardware Engine.

Intuitive Surgical, Inc. ISRG

Our call of ISRG yesterday morning couldn’t have been much better, with the stock putting forth a heck of a performance in the ensuing session. It traded in a range from 438.55 – 463.39 on the day, and as a result, anyone who was entertaining options calls as we pointed out had the chance to make substantial gains.

The landmark session came on the heels of two morning PR’s that you may want to click through to, below:

Facebook, Inc. FB Options

Another great call of ours this week was the FB Calls that we brought to the table first thing Monday morning, stating: “We’ll be looking to capitalize on the volatility that comes with rising anticipation of earnings, due for release on Wednesday.”, and noting that we’ve used this scenario to our advantage in the past.

Wednesday came and went, earnings exceeded expectations, and our FB Calls offered up big gains just as we surmised. The stock traded in a daily range from 69.61 – 71.33, and this morning in premarket trading, has reached as high as 78.44.

To adjust our strategy on FB options, we’ll be monitoring the $75-77 Calls as we head into week’s end.

Extended Watchlist:
ARIA, ONCO, CLSN, AGEN, JDST

DRRX, PPHM & Extended Watchlist

Durect Corp. DRRX

We are putting DRRX on our radar this morning; it has recently come off of a bottom, and is gaining some momentum as it begins its recovery. Prior to May, this pharmaceutical play was trading at a base level well above 1.20, before seeing a large spike followed by a sharp dropoff. If DRRX can break through resistance at the 50DMA & 200DMA there’s a chance it could come up to fill that gap on the chart. A return to previous levels from here could yield gains of up to 20%

In addition to a connection with pharma giant Pfizer, the company has also gotten FDA acceptance of a New Drug Application (NDA) as outlined in yesterday’s PR:

CUPERTINO, Calif., June 20, 2013 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. POSIDUR is a post-operative pain relief depot that utilizes DURECT’s patented SABER technology to deliver bupivacaine and is designed to provide up to three days of pain relief after surgery. DURECT submitted the NDA as a 505(b)(2) application. The Prescription Drug User Fee Act (PDUFA) goal date (the date the FDA expects to complete its review of the NDA) has been confirmed as February 12, 2014.

Peregrine Pharmaceuticals, Inc. PPHM

Speaking of pharmaceutical plays, one of the stocks that we continuously monitor is PPHM. Many of you will remember back in May when the stock provided us with some serious opportunities for profit.

Recently PPHM has been in a marked downtrend, and as you can see on the chart below, indicators seem to confirm this fact. We are going to want to put this one on bottom watch over the next several sessions, as the resulting bounce/s could be significant.

Side Note: 

Since Ben Bernanke’s recent comments regarding the Fed’s upcoming tapering of quantitative easing measures, markets have been in freefall. If no reversal occurs and that remains the overall trend, we are going to want to keep an eye on SPY Puts, VIX/VXX Calls.

Extended Watchlist:
ONCI, ONCO, LIVE, KERX, MSTX